
    
      The Objective of the trial is compare the efficacy and, secondarily, the safety and
      effectiveness of pre-procedural use of the Gp IIb/IIIa inhibitor eptifibatide in comparison
      to placebo in patients with diffuse CAD undergoing multiple DES implantation.
    
  